Comparative benefit-risk profile of induction and maintenance therapy with upadacitinib versus placebo in patients with moderately to severely active ulcerative colitis

被引：0
|
作者：
Blumenstein, I. [1 ]
Xuan, S. [2 ]
Panaccione, R. [3 ]
Baert, F. [4 ]
Barreiro-de Acosta, M. [5 ]
Ye, B. D. [6 ,7 ]
Klaff, J. [2 ]
Vladea, R. [2 ]
Levy, G. [2 ]
Holweg, C. T. J. [2 ]
Gonzalez, Y. Sanchez [2 ]
Dubinsky, M. C. [8 ]
机构：
[1] Goethe Univ Clin, Frankfurt, Germany
[2] AbbVie Inc, N Chicago, IL USA
[3] Univ Calgary, Dept Gastroenterol & Hepatol, Calgary, AB, Canada
[4] AZ Delta, Dept Gastroenterol, Roeselare, Belgium
[5] Univ Hosp Santiago de Compostela, Inflammatory Bowel Dis Unit, Galicia, Spain
[6] Univ Ulsan, Asan Med Ctr, Coll Med, Dept Gastroenterol, Seoul, South Korea
[7] Univ Ulsan, Inflammatory Bowel Dis Ctr, Seoul, South Korea
[8] Icahn Sch Med Mt Sinai, Susan & Leonard Feinstein IBD Ctr, New York, NY USA
来源：
JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P179
引用
收藏
页码：I333 / I334
页数：2
相关论文
共 50 条
  • [41] RISANKIZUMAB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: EFFICACY AND SAFETY IN THE RANDOMIZED PHASE 3 COMMAND
    Schreiber, Stefan
    Panaccione, Remo
    Parkes, Gareth C.
    Peyrin-Biroulet, Laurent
    Ferrante, Marc
    Hisamatsu, Tadakazu
    Siegmund, Britta
    Kalabic, Jasmina
    Levine, Phillip
    Neimark, Ezequiel
    Wallace, Kori
    Chen, Su
    Cheng, Ling
    Duan, W. Rachel
    Armuzzi, Alessandro
    Biedermann, Luc
    Loftus, Edward V.
    Melmed, Gil
    Louis, Edouard
    GASTROENTEROLOGY, 2024, 166 (05) : S238 - S238
  • [42] Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies
    Rubin, David T.
    Allegretti, Jessica R.
    Panes, Julian
    Shipitofsky, Nicole
    Yarandi, Shadi S.
    Huang, Kuan-Hsiang Gary
    Germinaro, Matthew
    Wilson, Rebbecca
    Zhang, Hongyan
    Johanns, Jewel
    Feagan, Brian G.
    Hisamatsu, Tadakazu
    Lichtenstein, Gary R.
    Bressler, Brian
    Peyrin-Biroulet, Laurent
    Sands, Bruce E.
    QUASAR Study Grp
    LANCET, 2025, 405 (10472): : 33 - 49
  • [43] Efficacy of Upadacitinib Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis by Biologic Inadequate Responder Status: Results From Two Randomized Phase 3 Studies
    Vermeire, Severine
    Tanida, Satoshi
    Hu, Renwei
    Panaccione, Remo
    Hebuterne, Xavier
    Rubin, David T.
    Ilo, Dapo
    Zhou, Wen
    Weinreich, Michael
    Zhou, Qing
    Danese, Silvio
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S398 - S399
  • [44] Adalimumab Induction Therapy Improves Health-Related Quality of Life in Patients with Moderately to Severely Active Ulcerative Colitis
    Reinisch, Walter
    Sandborn, William
    Thakkar, Roopal
    Lazar, Andreas
    Huang, Bidan
    Mulani, Parvez
    Chao, Jingdong
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 : S441 - S442
  • [45] Upadacitinib was not associated with anaemia in patients with moderately to severely active ulcerative colitis: Results from the U-ACHIEVE study
    D'Haens, G.
    Hebuterne, X.
    Higgins, P. D. R.
    Loftus, E. V., Jr.
    Zhou, W.
    Lacerda, A. P.
    Xie, W.
    Liu, J.
    Danese, S.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S580 - S581
  • [46] UPADACITINIB WAS NOT ASSOCIATED WITH ANAEMIA IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE U-ACHIEVE STUDY
    D'Haens, Geert R.
    Hebuterne, Xavier
    Higgins, Peter D.
    Loftus, Edward V.
    Zhou, Wen
    Lacerda, Ana P.
    Xie, Wangang
    Liu, Jianzhong
    Danese, Silvio
    GASTROENTEROLOGY, 2020, 158 (06) : S1205 - S1206
  • [47] Long-Term Benefit of Golimumab for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension
    Reinisch, Walter
    Gibson, Peter R.
    Sandborn, William J.
    Feagan, Brian G.
    Strauss, Richard
    Johanns, Jewel
    Padgett, Lakshmi
    Adedokun, Omoniyi J.
    Colombel, Jean-Frederic
    Collins, Judith
    Rutgeerts, Paul
    Tarabar, Dino
    Marano, Colleen
    JOURNAL OF CROHNS & COLITIS, 2018, 12 (09): : 1053 - 1066
  • [48] Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study
    Vermeire, Severine
    Lakatos, Peter L.
    Ritter, Timothy
    Hanauer, Stephen
    Bressler, Brian
    Khanna, Reena
    Isaacs, Kim
    Shah, Saumin
    Kadva, Alysha
    Tyrrell, Helen
    Oh, Young S.
    Tole, Swati
    Chai, Akiko
    Pulley, Jennifer
    Eden, Christopher
    Zhang, Wenhui
    Feagan, Brian G.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (01): : 28 - 37
  • [49] EFFECT OF UPADACITINIB ON LIPID PROFILES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: POOLED ANALYSIS OF PHASE 3 INDUCTION AND MAINTENANCE STUDIES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE OR ULCERATIVE COLITIS
    Dubinsky, Marla C.
    Ha, Christina
    Armuzzi, Alessandro
    Irving, Peter M.
    Fumery, Mathurin
    Anyanwu, Samuel
    Lacerda, Ana P.
    Wang, Tao
    Suravaram, Smitha
    Kligys, Kristina
    Shah, Saajan
    Duncan, Benjamin
    Rubin, David T.
    GASTROENTEROLOGY, 2024, 166 (05) : S813 - S813
  • [50] Pharmacokinetics of Adalimumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
    Awni, Walid M.
    Eckert, Doerthe
    Sharma, Shringi
    Mostafa, Nael M.
    Noertersheuser, Peter A.
    Pradhan, Rajendra S.
    Robinson, Anne
    Sandborn, William
    Hanauer, Stephen B.
    Colombel, Jean-Frederic
    Thakkar, Roopal
    GASTROENTEROLOGY, 2013, 144 (05) : S229 - S229
12345